Evidence map›Paper›PMID 38288829›Full record

ArticleCurrent radiopharmaceuticals2024

Hepatopulmonary Shunt Ratio Verification Model for Transarterial Radioembolization.

Nami Yeyin, Fahrettin Fatih Kesmezacar, Duygu Tunçman, Özge Demir, Lebriz Uslu-Beşli, Osman Günay, Mustafa Demir

Abstract read
PubMed Publisher
In one paragraph

Article in Current radiopharmaceuticals, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Separation ofMolecular imaging and radionuclide therapy · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nami YeyinDepartment of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Fatih/Istanbul, Turkey.ORCID 0000-0003-0262-4020
Fahrettin Fatih KesmezacarVocational School of Health Service, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID 0000-0001-5110-1184
Duygu TunçmanVocational School of Health Service, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID 0000-0002-0929-0441
Özge DemirDepartment of Chemical Engineering, Engineering Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID 0000-0002-0342-5915
Lebriz Uslu-BeşliDepartment of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Fatih/Istanbul, Turkey.ORCID 0000-0003-1868-3957
Osman GünayDepartment of Biomedical Engineering, Faculty of Electrical and Electronics Engineering, Yıldız Technical University, Istanbul, Turkey.
Mustafa DemirDepartment of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Fatih/Istanbul, Turkey.ORCID 0000-0002-9813-1628
Istanbul University-Cerrahpaşa · TRYıldız Technical University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe most important toxicity of transarterial radioembolization therapy applied in liver malignancies is radiation pneumonitis and fibrosis due to hepatopulmonary shunt of Yttrium-90 ( MATERIALS AND

methodsA 3D-printed lung and liver phantom containing two liver tumors was developed from Polylactic Acid (PLA) material, which is similar to the normal-sized human body in terms of texture and density. Actual %LSFs were calculated by filling phantoms and tumors with

resultsIn our experimental model, LSFs calculated from

conclusionLSF is critical in dosimetry calculations of

Indexed as

Embolization, TherapeuticLiver NeoplasmsPhantoms, ImagingRadiopharmaceuticalsTechnetium Tc 99m Aggregated AlbuminYttrium RadioisotopesHumansLiverLungMicrospheresPrinting, Three-DimensionalSingle Photon Emission Computed Tomography Computed TomographyRadiopharmaceuticalsTechnetium Tc 99m Aggregated AlbuminYttrium-90Yttrium Radioisotopes90Y microsphere therapyhepatopulmonary phantomliver tumors.Lung shunt fractionradionuclide dosimetrytransarterial radioembolization

Identifiers

PMID38288829
OpenAlexW4391310716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.